Jan Poolman
Script error: No such module "Draft topics". Script error: No such module "AfC topic". Script error: No such module "AfC submission catcheck".
Jan T Poolman Ph.D. (1951) is a Dutch microbiologist and bacterial vaccine expert. His life has been dedicated to the discovery and development of bacterial vaccines. He is known for his role in the development of meningococcal, pneumococcal, pertussis, Haemophilus influenzae type b (Hib), E. coli and S. aureus vaccines.[1][2][3]
Education and Research[edit]
Poolman earned his master’s degree from the University of Amsterdam (UVA) in 1975, where he studied chemistry and specialized in the field of microbiology.
He started his career as assistant-professor at the University of Amsterdam, Medical Microbiology department (1975-1986) and the Dutch Reference Laboratory for Bacterial Meningitis, including a NIH Fogarty Fellowship in 1982 and a thesis on the meningococcal cell surface structure.[4] Next he became head of Bacterial Vaccine Research & Development (R&D) at the Dutch National Public Health Institute (RIVM, 1986-1996) initiating DTaPIPVHib, meningococcal and pneumococcal vaccine R&D activities, also acting as project leader for the newly created Dutch-Nordic Consortium combining activities from the Dutch and Scandinavian Public Health Institutes with a focus on pneumococcal vaccine R&D.[2][3]
He then moved on to SmithKline Beecham Biologicals (now GSK Vaccines) in Rixensart, Belgium (1997-2011) as head of bacterial vaccine R&D contributing to the licensure of several bacterial vaccines including whole cell and acellular pertussis and Hib combinations, meningococcal and pneumococcal vaccines. From GSK Dr Poolman moved back from Belgium to The Netherlands to join the vaccine endeavor by Johnson & Johnson (2011-2024), creating a Bacterial Vaccine R&D team with projects centered around adult bacterial vaccines aiming to prevent bacteremia and sepsis induced by E. coli and S. aureus. Extraintestinal Pathogenic E. coli ExPEC 9-valent O-polysaccharide conjugate is currently undergoing a phase 3 efficacy study evaluation.[5]
After his retirement in September 2024 from Johnson & Johnson, Dr Poolman now functions as scientific advisor for several companies/organizations.
Selected publications[edit]
Group B Meningococcus:
Cartwright, K; Morris, R; Rümke, H; Fox, A; Borrow, R; Begg, N; Richmond, P; Poolman, J (1999) Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine Vol. 17 (20-21) pp 2612-2619. Doi: 10.1016/s0264-410x(99)00044-4
Haemophilus influenzae type b (Hib):
Poolman, J; Kaufhold, A; De Grave, D; Goldblatt, D (2001) Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine Vol. 19 (17-19) pp 2280-2285. Doi: 10.1016/s0264-410x(00)00517-x
Pertussis:
Capiau, C; Poolman, J; Hoet, B; Bogaerts, H; Andre, F (2003) Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: Difficulties encountered and lessons learned. Vaccine Vol. 21 (19-20) pp 2273-2287. Doi: 10.1016/s0264-410x(03)00107-5
Pneumococcus:
Prymula, R; Peeters, P; Chrobok, V; Kriz, P; Novakova, E; Kaliskova, E; Kohl, I; Lommel, P; Poolman, J; Prieels, JP; Schuerman, L (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. The Lancet Vol. 367 No. 9512 pp 740-748. Doi: 10.1016/S0140-6736(06)68304-9
Meningococcus ACWY:
Knuf, M; Kieninger-Baum, D; Habermehl, P; Muttonen, P; Maurer, H; Vink, P; Poolman, J; Boutriau, D (2010) A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine Vol. 28 (3) pp 744-53. Doi: 10.1016/j.vaccine.2009.10.064
ExPEC:
Huttner, A; Hatz, C; van den Dobbelsteen, G; Abbanat, D; Hornacek, A; Frölich, R; Dreyer, AM; Martin, P; Davies, T; Fae, K; van den Nieuwenhof, I; Thoelen, S; de Vallière, S; Kuhn, A; Bernasconi, E; Viereck, V; Kavvadias, T; Kling, K; Ryu, G; Hülder, T; Gröger, S; Scheiner, D; Alaimo, C; Harbarth, S; Poolman, J; Fonck, VG (2017) Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017 May;17(5):528-537. Doi: 10.1016/S1473-3099(17)30108-1
S. aureus:
Fernandez, J; Sanders, H; Henn, J; Wilson, JM; Malone, D; Buoninfante, A; Willms, M; Chan, R; DuMont, AL; McLahan, C; Grubb, K; Romanello, A; van den Dobbelsteen, G; Torres, VJ; Poolman, JT (2022) Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model. J Infect Dis. Vol. 225 (8) pp 1460-1470. Doi: 10.1093/infdis/jiab219
Personal life[edit]
Poolman is born 16 June 1951 in Broek op Waterland, the Netherlands; he is married and jointly with his second wife they have a mixed family with five children and two grandchildren.
References[edit]
- ↑ Poolman, Jan (2018-12-02). "Building teams to create innovative new vaccines". Human Vaccines & Immunotherapeutics. 14 (12): 2808–2810. doi:10.1080/21645515.2018.1530523. ISSN 2164-5515. PMC 6351015. PMID 30346885.
- ↑ 2.0 2.1 Hendriks, Jan; Blume, Stuart (2016-07-07). "Why might regional vaccinology networks fail? The case of the Dutch-Nordic Consortium". Globalization and Health. 12 (1): 38. doi:10.1186/s12992-016-0176-6. ISSN 1744-8603. PMC 4936226. PMID 27388678.
- ↑ 3.0 3.1 Blume, Stuart S.; Baylac-Paouly, Baptiste (2022). Immunization and states: the politics of making vaccines. Abingdon, Oxon New York, NY: Routledge. ISBN 978-0-367-67227-0. Search this book on
- ↑ "Album Academicum". albumacademicum.uva.nl. Retrieved 2024-04-22.
- ↑ Janssen Research & Development, LLC (2024-03-26). "Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years (Report). clinicaltrials.gov.ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-07-03.
This article "Jan Poolman" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Jan Poolman. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
